• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

6.400 +0.100 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 531,933
Open 6.230
Bid (Size) 6.300 (8)
Ask (Size) 6.400 (2)
Prev. Close 6.300
Today's Range 6.190 - 6.410
52wk Range 5.710 - 17.57
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From Evolus
Via Business Wire
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2025
From Evolus
Via Business Wire

Performance

YTD
-42.4%
-42.4%
1 Month
-1.8%
-1.8%
3 Month
-31.5%
-31.5%
6 Month
-40.7%
-40.7%
1 Year
-63.3%
-63.3%

More News

Read More
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
September 08, 2025
From Evolus
Via Business Wire
Earnings Scheduled For August 5, 2025
August 05, 2025
Via Benzinga
A Look Ahead: Evolus's Earnings Forecast
August 04, 2025
Via Benzinga
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
August 25, 2025
From Evolus
Via Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
August 20, 2025
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From Evolus
Via Business Wire
What's going on in today's session
August 06, 2025
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 06, 2025
Via Benzinga
Here are the top movers in Wednesday's session.
August 06, 2025
Via Chartmill
The market is filled with gapping stocks in Wednesday's session.
August 06, 2025
Via Chartmill
Evolus (EOLS) Q2 Revenue Rises 4%
August 06, 2025
Via The Motley Fool
Topics Economy
Discover the top movers in Wednesday's pre-market session.
August 06, 2025
Via Chartmill
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 06, 2025
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 06, 2025
Via Benzinga
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
August 06, 2025
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 05, 2025
Via Benzinga
Top movers in Tuesday's after hours session
August 05, 2025
Via Chartmill
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 05, 2025
From Evolus
Via Business Wire
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
July 31, 2025
From Evolus
Via Business Wire
Evolus to Report Second Quarter Financial Results on August 5, 2025
July 22, 2025
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From Evolus
Via Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
July 09, 2025
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From Evolus
Via Business Wire

Frequently Asked Questions

Is Evolus, Inc. - Common Stock publicly traded?
Yes, Evolus, Inc. - Common Stock is publicly traded.
What exchange does Evolus, Inc. - Common Stock trade on?
Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Evolus, Inc. - Common Stock?
The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
What is the current price of Evolus, Inc. - Common Stock?
The current price of Evolus, Inc. - Common Stock is 6.400
When was Evolus, Inc. - Common Stock last traded?
The last trade of Evolus, Inc. - Common Stock was at 10/17/25 04:00 PM ET
What is the market capitalization of Evolus, Inc. - Common Stock?
The market capitalization of Evolus, Inc. - Common Stock is 349.29M
How many shares of Evolus, Inc. - Common Stock are outstanding?
Evolus, Inc. - Common Stock has 349M shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap